CellaVision
195.2
SEK
-1.31 %
1,483 following
CEVI
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
-1.31%
+20.2%
+9.54%
-10.25%
-11.87%
-23.45%
-43.5%
-33.83%
+1,151.28%
CellaVision operates in the medical technology industry and focuses on the development and manufacture of systems for digital blood analysis. The company focuses on digital cell morphology and offers innovations for analyzers, instruments, reagents and software used in hematology laboratories. The company's products are aimed at healthcare institutions and laboratories worldwide. CellaVision was founded in 1994 and is headquartered in Lund, Sweden.
Read moreMarket cap
4.66B SEK
Turnover
1.89M SEK
Revenue
723.22M
EBIT %
24.57 %
P/E
33.08
Dividend yield-%
1.28 %
Financial calendar
18/7
2025
Interim report Q2'25
6/11
2025
Interim report Q3'25
5/2
2026
Annual report '25
All
Webcasts
Press releases
ShowingAll content types
CellaVision AB announces change in management team
Kommuniké från årsstämma i CellaVision AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Bulletin from the Annual General Meeting of CellaVision AB (publ)
Redeye: Cellavision Q1 2025 - EMEA Drove Sales Growth

CellaVision, Audiocast with teleconference, Q1'25
Starkt kvartal i en dynamisk omvärld
Strong quarter in a rapidly changing environment
Modular Finance IR Consensus: CellaVision – Consensus estimates Q1 2025
Inbjudan till presentation av CellaVisions rapport för första kvartalet 2025, den 29 april kl. 11:00
Invitation to Presentation of the CellaVision Report for the First Quarter 2025 on April 29, at 11:00 CEST
CellaVision publicerar års- och hållbarhetsredovisning för 2024
CellaVision publishes its 2024 Annual and Sustainability Report
KALLELSE TILL ÅRSSTÄMMA i CELLAVISION AB (PUBL)
NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)
